Brivanib alaninate (BioDeep_00000706855)
代谢物信息卡片
化学式: C22H24FN5O4 (441.1812236)
中文名称: 丙氨酸布立尼布
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)OC(=O)C(C)N)C
InChI: InChI=1S/C22H24FN5O4/c1-11-7-15-16(27-11)5-6-17(19(15)23)32-21-20-13(3)18(8-28(20)26-10-25-21)30-9-12(2)31-22(29)14(4)24/h5-8,10,12,14,27H,9,24H2,1-4H3/t12-,14+/m1/s1
描述信息
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
同义名列表
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:167656
- KEGGdrug: D08878
- PubChem: 11154925
- DrugBank: DB11865
- ChEMBL: CHEMBL270995
- CAS: 649735-63-7
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yihong Wan, Wenyu Wu, Yuanda Wan, Liren Li, Jiawen Zhang, Xiaoguang Chen, Shuwen Liu, Xingang Yao. Brivanib alaninate inhibited dengue virus proliferation through VEGFR2/AMPK pathway.
Pharmacological research.
2021 08; 170(?):105721. doi:
10.1016/j.phrs.2021.105721. [PMID: 34116207] - Jakub Hofman, Ales Sorf, Dimitrios Vagiannis, Simona Sucha, Sarah Kammerer, Jan-Heiner Küpper, Si Chen, Lei Guo, Martina Ceckova, Frantisek Staud. Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes.
Molecular pharmaceutics.
2019 11; 16(11):4436-4450. doi:
10.1021/acs.molpharmaceut.9b00361. [PMID: 31633365] - Kyoung Doo Song, Dongil Choi, Jung Hee Lee, Geun Ho Im, Jehoon Yang, Jae-Hun Kim, Won Jae Lee. Evaluation of tumor microvascular response to brivanib by dynamic contrast-enhanced 7-T MRI in an orthotopic xenograft model of hepatocellular carcinoma.
AJR. American journal of roentgenology.
2014 Jun; 202(6):W559-66. doi:
10.2214/ajr.13.11042. [PMID: 24848850] - Han-Chieh Lin, Yi-Tsau Huang, Ying-Ying Yang, Pei-Chang Lee, Lih-Hwa Hwang, Wei-Ping Lee, Ying-Ju Kuo, Kuei-Chuan Lee, Yun-Cheng Hsieh, Ren-Shyan Liu. Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats.
Journal of gastroenterology and hepatology.
2014 May; 29(5):1073-82. doi:
10.1111/jgh.12480. [PMID: 24325631] - Ying-Ying Yang, Ren-Shyan Liu, Pei-Chang Lee, Yi-Chen Yeh, Yi-Tsau Huang, Wei-Ping Lee, Kuei-Chuan Lee, Yun-Cheng Hsieh, Fa-Yauh Lee, Tat-Wei Tan, Han-Chieh Lin. Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.
Liver international : official journal of the International Association for the Study of the Liver.
2014 Apr; 34(4):521-34. doi:
10.1111/liv.12299. [PMID: 23998651] - Ezia Bello, Giulia Taraboletti, Gennaro Colella, Massimo Zucchetti, Daniele Forestieri, Simonetta A Licandro, Alexander Berndt, Petra Richter, Maurizio D'Incalci, Ennio Cavalletti, Raffaella Giavazzi, Gabriella Camboni, Giovanna Damia. The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.
Molecular cancer therapeutics.
2013 Feb; 12(2):131-40. doi:
10.1158/1535-7163.mct-12-0275-t. [PMID: 23270924] - Jiachang Gong, Jinping Gan, Eric Masson, Shariq Syed, Yuan-Qing Xia, Daphne Williams, Janice Pursley, Mohammed Jemal, W Griff Humphreys, Ramaswamy A Iyer. Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology.
Drug metabolism and disposition: the biological fate of chemicals.
2012 Dec; 40(12):2374-80. doi:
10.1124/dmd.112.047340. [PMID: 22983304] - Jiachang Gong, Jinping Gan, Janet Caceres-Cortes, Lisa J Christopher, Vinod Arora, Eric Masson, Daphne Williams, Janice Pursley, Alban Allentoff, Michael Lago, Scott B Tran, Ramaswamy A Iyer. Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
Drug metabolism and disposition: the biological fate of chemicals.
2011 May; 39(5):891-903. doi:
10.1124/dmd.110.037341. [PMID: 21289073] - Tarek Mekhail, Eric Masson, Bruce S Fischer, Jiachang Gong, Ramaswamy Iyer, Jinping Gan, Janice Pursley, Daniel Patricia, Daphne Williams, Ram Ganapathi. Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
Drug metabolism and disposition: the biological fate of chemicals.
2010 Nov; 38(11):1962-6. doi:
10.1124/dmd.110.033951. [PMID: 20671097] - Rajeev S Bhide, Louis J Lombardo, John T Hunt, Zhen-Wei Cai, Joel C Barrish, Susan Galbraith, Robert Jeyaseelan, Steven Mortillo, Barri S Wautlet, Bala Krishnan, Daniel Kukral, Harold Malone, Anne C Lewin, Benjamin J Henley, Joseph Fargnoli. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.
Molecular cancer therapeutics.
2010 Feb; 9(2):369-78. doi:
10.1158/1535-7163.mct-09-0472. [PMID: 20103604] - Punit H Marathe, Amrita V Kamath, Yueping Zhang, Celia D'Arienzo, Rajeev Bhide, Joseph Fargnoli. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Cancer chemotherapy and pharmacology.
2009 Dec; 65(1):55-66. doi:
10.1007/s00280-009-1002-0. [PMID: 19396600]